Cognition Therapeutics Inc (CGTX) Stock Price, Quote & News

Company Profile

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as ge...

Industry: Biotechnology

Sector: Healthcare

Phone: 412 481 2210

Website: www.cogrx.com

Address:

2500 Westchester Ave., Purchase, United States

OLDjimmy2shoes Jun. 27 at 2:16 PM

$CGTX All we all know we need a buyout or partnership, but what does everyone think the likelihood is that it happens in July, post FDA meeting? If there were ever a time, that would be it with the RS looming and cash runway expiring at the end of this year.

1 · Reply

OLDjimmy2shoes Jun. 27 at 12:55 PM

$CGTX don't go up! I want to buy more in the .20s!!!!!!

1 · Reply

Perillo1983 Jun. 27 at 10:49 AM

$CGTX Today we lift off

0 · Reply

fabsleme Jun. 26 at 10:35 PM

$CGTX lets goooo tomorrow we got a banger.. Cheers..

0 · Reply

bfelcan Jun. 26 at 8:48 PM

$CGTX ive been here a longggg time..nice to see some green. Though idk if it'll hold i think the only way out is partnership or buyout. I love the stock though! It just dont love me lol

1 · Reply

GibsonFlyingV Jun. 26 at 8:40 PM

$CGTX pretty solid day. Loaded up and will continue to.

0 · Reply

FitzCatalyst Jun. 26 at 8:15 PM

$CGTX good day

0 · Reply

Danadamholly Jun. 26 at 5:41 PM

$CGTX I’m in let’s see what happens after July 👍

1 · Reply

Logic102 Jun. 26 at 4:42 PM

$CGTX $LCTX H.C. Wainwright is going out on a limb with 10 bagger price targets on both of these companies. Analyst PTs can often be taken with a cup full of salt, but predicting such huge gains is highly unusual. Two underpriced gems here IMO.

2 · Reply

fabsleme Jun. 26 at 4:25 PM

$CGTX come on.. lets gooooo build for greatness this GEM. AT LEAST .50 CENTS

0 · Reply

Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer's Disease and Dementia with Lewy Bodies (DLB)

Jun 3, 2025, 7:30 AM EDT - 24 days ago

Philanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

May 28, 2025, 7:30 AM EDT - 4 weeks ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies

May 9, 2025, 7:30 AM EDT - 7 weeks ago

Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health

May 7, 2025, 7:30 AM EDT - 7 weeks ago

Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update

Apr 1, 2025, 7:30 AM EDT - 3 months ago

Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes

Mar 25, 2025, 7:30 AM EDT - 3 months ago

Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025

Mar 20, 2025, 1:15 PM EDT - 3 months ago

Cognition Therapeutics, Inc (CGTX) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 7:00 AM EDT - 3 months ago

Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update

Mar 13, 2025, 4:05 PM EDT - 3 months ago

Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results

Mar 12, 2025, 4:05 PM EDT - 3 months ago

Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing

Mar 10, 2025, 7:30 AM EDT - 3 months ago

Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference

Feb 27, 2025, 7:30 AM EST - 4 months ago

Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD

Feb 25, 2025, 7:30 AM EST - 4 months ago

Cognition Therapeutics' VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit

Jan 30, 2025, 7:30 AM EST - 5 months ago

Cognition's Positive Phase 2 ‘SHIMMER' Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC

Jan 8, 2025, 4:14 PM EST - 6 months ago

Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences

Dec 18, 2024, 11:06 AM EST - 6 months ago

Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday?

Dec 18, 2024, 7:22 AM EST - 6 months ago

Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

Nov 26, 2024, 7:30 AM EST - 7 months ago

Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies

Nov 25, 2024, 7:30 AM EST - 7 months ago

Cognition Therapeutics' Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer's Population

Nov 13, 2024, 7:30 AM EST - 8 months ago

Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

Nov 12, 2024, 7:30 AM EST - 8 months ago

Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

Oct 31, 2024, 4:15 PM EDT - 8 months ago

Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

Oct 29, 2024, 12:55 PM EDT - 8 months ago

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

Oct 23, 2024, 7:30 AM EDT - 8 months ago

Analyses from Cognition's Positive Phase 2 ‘SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTAD

Oct 22, 2024, 7:30 AM EDT - 8 months ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

Oct 2, 2024, 7:30 AM EDT - 9 months ago

Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference

Oct 1, 2024, 7:30 AM EDT - 9 months ago

Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia

Sep 3, 2024, 7:30 AM EDT - 10 months ago

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

Aug 22, 2024, 7:31 AM EDT - 11 months ago

Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease

Aug 11, 2024, 12:55 AM EDT - 11 months ago

Cognition Therapeutics, Inc. (CGTX) Q1 2024 Earnings Call Transcript

Aug 8, 2024, 7:00 AM EDT - 11 months ago

Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update

Aug 5, 2024, 7:30 AM EDT - 11 months ago

Cognition Therapeutics to Report Second Quarter 2024 Financial Results

Jul 29, 2024, 7:14 AM EDT - 11 months ago

Cognition Therapeutics announces positive results from trial of oral treatment for mild-to-moderate Alzheimer's disease

Jul 29, 2024, 7:00 AM EDT - 11 months ago

Cognition Therapeutics' Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer's Patients

Jul 26, 2024, 4:11 PM EDT - 11 months ago

Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease at 8:30am ET on Monday July 29, 2024

Jul 2, 2024, 7:30 AM EDT - 1 year ago

Results from Cognition Therapeutics' Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease Accepted for Presentation at AAIC

May 21, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease

May 7, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update

Apr 29, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies

Apr 22, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer's Disease

Apr 2, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference

Apr 1, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer's Disease on April 12, 2024

Mar 26, 2024, 12:02 PM EDT - 1 year ago

Cognition Therapeutics, Inc. (CGTX) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 7:00 AM EDT - 1 year ago

Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update

Mar 15, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results

Mar 14, 2024, 4:05 PM EDT - 1 year ago

Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock

Mar 11, 2024, 8:16 PM EDT - 1 year ago

Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock

Mar 11, 2024, 4:05 PM EDT - 1 year ago

Cognition Therapeutics Announces Proposed Public Offering of Common Stock

Mar 6, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer's Disease Studies

OLDjimmy2shoes Jun. 27 at 2:16 PM

1 · Reply

OLDjimmy2shoes Jun. 27 at 12:55 PM

$CGTX don't go up! I want to buy more in the .20s!!!!!!

1 · Reply

Perillo1983 Jun. 27 at 10:49 AM

$CGTX Today we lift off

0 · Reply

fabsleme Jun. 26 at 10:35 PM

$CGTX lets goooo tomorrow we got a banger.. Cheers..

0 · Reply

bfelcan Jun. 26 at 8:48 PM

$CGTX ive been here a longggg time..nice to see some green. Though idk if it'll hold i think the only way out is partnership or buyout. I love the stock though! It just dont love me lol

1 · Reply

GibsonFlyingV Jun. 26 at 8:40 PM

$CGTX pretty solid day. Loaded up and will continue to.

0 · Reply

FitzCatalyst Jun. 26 at 8:15 PM

$CGTX good day

0 · Reply

Danadamholly Jun. 26 at 5:41 PM

$CGTX I’m in let’s see what happens after July 👍

1 · Reply

Logic102 Jun. 26 at 4:42 PM

2 · Reply

fabsleme Jun. 26 at 4:25 PM

$CGTX come on.. lets gooooo build for greatness this GEM. AT LEAST .50 CENTS

0 · Reply

JarvisFlow Jun. 26 at 12:00 PM

HC Wainwright & Co. has updated their rating for Cognition Therapeutics ( $CGTX ) to Buy with a price target of 3.

0 · Reply

OLDjimmy2shoes Jun. 26 at 11:49 AM

$CGTX Rank these in order of what is holding this back. Cannot add anything to my list (I know there are others). Shorts Volume ATM

2 · Reply

SMTM_Plz Jun. 26 at 4:34 AM

$CGTX Zervimesine Alzheimer : EOP2 meeting on July 9, 2025 DLB : IND application > reviews applications for breakthrough designation within 60 days.(maybe end of August)

1 · Reply

Dmsrz8 Jun. 26 at 4:14 AM

$CGTX hopefully this finds some consistency soon

0 · Reply

OLDjimmy2shoes Jun. 26 at 1:01 AM

$CGTX

0 · Reply

Wristburn Jun. 25 at 9:37 PM

$CGTX Just keep buying. The current approved and non-approved medications for AD and DLB are trash.

0 · Reply

ROMEO44 Jun. 25 at 9:35 PM

$CGTX mm were manipulating ah i put in a 10k bid at .28 and they filled it --hmmmm maybe a little covering going on

2 · Reply

OLDjimmy2shoes Jun. 25 at 8:36 PM

$CGTX WTF just happened?

2 · Reply

fabsleme Jun. 25 at 7:21 PM

$CGTX lets close at .35

0 · Reply

OLDjimmy2shoes Jun. 25 at 6:09 PM

$CGTX Alright homies, plan is to get back in this time next week. We all know shit ain't happening until July. I will be back. We will be brothers in arms. Your pain is my pain. One day we will look back and laugh about how Lisa pulled our dicks for months, only to slap down a 8 figure buyout deal on the table.

1 · Reply

FitzCatalyst Jun. 25 at 6:02 PM

$CGTX 🫤

0 · Reply

fabsleme Jun. 25 at 5:40 PM

$CGTX lets turn this ship around Dementia is on the horizon.

0 · Reply

Market Cap	18.60M
Revenue (ttm)	0.00
Net Income (ttm)	-33.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,045,400
Avg Vol	1,273,564
Day's Range	N/A - N/A
Shares Out	61.99M
Stochastic %K	92%
Beta	0.75
Analysts	Strong Sell
Price Target	$4.00